Hospital
Mclaren Flint
Mclaren Flint was paid $43.44M by Medicaid between Jan 2018 and Dec 2024, across 417 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoMCLAREN FLINT
FLINT, MI 48532
FLINT, MI 48532
33aNPI1902894512assigned 10/07/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$43.44M
24GClaims1,472,842
24DCodes billed417
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#27 of 86
Median peer was paid$21.55M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KORTE, FRED controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 219,777 | $7.12M | |
| 2019 | 248,221 | $7.18M | |
| 2020 | 193,938 | $5.64M | |
| 2021 | 206,966 | $5.78M | |
| 2022 | 187,859 | $5.48M | |
| 2023 | 227,000 | $6.41M | |
| 2024incomplete | 189,081 | $5.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 48,842 | 44,351 | $8.83M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 23,344 | 21,280 | $8.18M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 43,183 | 39,761 | $5.21M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.3% | 29,797 | 26,928 | $2.31M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.0% | 41,079 | 35,136 | $1.32M |
| 93458 | 2.6% | 1,078 | 1,016 | $1.13M | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.6% | 3,359 | 3,271 | $1.11M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 6,895 | 6,661 | $957K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 9,281 | 8,850 | $887K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 9,242 | 8,832 | $742K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.5% | 1,416 | 1,380 | $668K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 23,200 | 5,659 | $620K |
405 more codes
| 80061 | Lipid panel | 1.4% | 12,477 | $592K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 9,057 | $553K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 6,845 | $536K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 19,364 | $535K |
| 82947 | 1.2% | 11,944 | $515K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 21,495 | $493K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.1% | 1,049 | $490K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,771 | $406K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 6,997 | $388K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 11,039 | $327K |
| G0378 | Hospital observation service, per hour | <1% | 7,496 | $289K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,487 | $282K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,170 | $255K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,231 | $252K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,690 | $231K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,870 | $220K |
| 76830 | Ultrasound, transvaginal | <1% | 4,164 | $217K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,321 | $201K |
| 76801 | <1% | 3,611 | $188K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 495 | $183K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,710 | $178K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 345 | $149K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,559 | $144K |
| 59025 | Fetal non-stress test | <1% | 1,774 | $137K |
| 95811 | <1% | 290 | $134K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 874 | $134K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,633 | $133K |
| 74178 | <1% | 812 | $132K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 215 | $131K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,573 | $129K |
| 97161 | <1% | 2,809 | $128K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,986 | $105K |
| 93971 | <1% | 2,256 | $101K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 820 | $100K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,239 | $74K |
| 76641 | <1% | 1,530 | $71K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 157 | $70K |
| 76770 | <1% | 1,416 | $70K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,151 | $65K |
| 72141 | <1% | 538 | $65K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,974 | $65K |
| 77336 | <1% | 1,064 | $59K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 86 | $56K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 897 | $56K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,246 | $56K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,539 | $55K |
| 90837 | Psychotherapy session, about an hour | <1% | 683 | $55K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,011 | $55K |
| 71250 | <1% | 1,296 | $52K | |
| 76536 | <1% | 1,109 | $48K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,970 | $47K |
| 72131 | <1% | 1,362 | $47K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,247 | $45K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,735 | $45K |
| 93976 | <1% | 1,170 | $44K | |
| 70486 | <1% | 1,329 | $43K | |
| 93798 | <1% | 854 | $43K | |
| 50590 | <1% | 30 | $42K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,330 | $42K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,686 | $42K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,058 | $38K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,270 | $37K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 713 | $36K |
| 86900 | <1% | 5,380 | $31K | |
| 93970 | <1% | 400 | $30K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 20,424 | $28K |
| 77334 | <1% | 102 | $27K | |
| 70496 | <1% | 493 | $27K | |
| 43235 | <1% | 78 | $26K | |
| 71271 | <1% | 466 | $26K | |
| 10060 | <1% | 299 | $24K | |
| 72110 | <1% | 1,247 | $22K | |
| 77412 | <1% | 243 | $21K | |
| 80053 | Comprehensive metabolic panel | <1% | 48,589 | $21K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 400 | $21K |
| 93975 | <1% | 200 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,356 | $20K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 484 | $20K |
| 96367 | <1% | 698 | $19K | |
| 73221 | <1% | 156 | $18K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 75,773 | $18K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 509 | $17K |
| 74018 | <1% | 1,345 | $15K | |
| 77300 | <1% | 96 | $15K | |
| 70491 | <1% | 167 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,121 | $13K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 472 | $13K |
| 72100 | <1% | 679 | $13K | |
| 73030 | <1% | 2,627 | $12K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,795 | $12K |
| 77065 | Tomosynthesis, mammo | <1% | 340 | $12K |
| 73562 | <1% | 3,156 | $12K | |
| 90686 | <1% | 749 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 258 | $10K |
| 73630 | <1% | 3,378 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 52,985 | $10K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 272 | $10K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 595 | $9K |
| Q3014 | Telehealth originating site facility fee | <1% | 757 | $9K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 552 | $9K |
| 97116 | <1% | 700 | $9K | |
| 76000 | <1% | 383 | $8K | |
| G0008 | Administration of influenza virus vaccine | <1% | 800 | $8K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 98 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,624 | $8K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 232 | $8K |
| 87480 | <1% | 3,774 | $8K | |
| 95806 | <1% | 94 | $8K | |
| 87510 | <1% | 3,773 | $8K | |
| 87660 | <1% | 3,767 | $7K | |
| 73502 | <1% | 1,280 | $7K | |
| 77301 | <1% | 15 | $7K | |
| 87070 | <1% | 3,967 | $6K | |
| 87390 | <1% | 2,177 | $6K | |
| 73130 | <1% | 3,260 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,122 | $6K |
| 72158 | <1% | 40 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 29,182 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,841 | $6K |
| 73610 | <1% | 2,700 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 803 | $5K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,728 | $5K |
| 97165 | <1% | 177 | $5K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 155 | $5K |
| 82728 | <1% | 3,019 | $4K | |
| 84702 | <1% | 5,030 | $4K | |
| 83550 | <1% | 2,959 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 17 | $4K |
| 86702 | <1% | 2,205 | $4K | |
| 82607 | <1% | 3,070 | $3K | |
| 96130 | <1% | 26 | $3K | |
| 73110 | <1% | 1,845 | $3K | |
| 84439 | <1% | 4,625 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,215 | $3K |
| J3490 | Unclassified drugs | <1% | 20,372 | $3K |
| 86850 | <1% | 4,616 | $3K | |
| 80074 | <1% | 485 | $3K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 196 | $3K |
| 97162 | <1% | 75 | $3K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 27 | $3K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,487 | $3K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 15 | $3K |
| 91010 | <1% | 13 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,346 | $3K |
| 86592 | <1% | 969 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 47 | $2K |
| 86701 | <1% | 2,200 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 421 | $2K |
| 85610 | <1% | 16,019 | $2K | |
| 83540 | <1% | 3,326 | $2K | |
| 87186 | <1% | 2,584 | $2K | |
| 86780 | <1% | 661 | $2K | |
| 10061 | <1% | 13 | $2K | |
| 87081 | <1% | 3,349 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,845 | $2K |
| 85027 | <1% | 5,720 | $2K | |
| 81025 | <1% | 27,236 | $2K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 65 | $2K |
| 87340 | <1% | 1,390 | $2K | |
| 85730 | <1% | 12,565 | $2K | |
| 83735 | <1% | 13,057 | $2K | |
| 87077 | <1% | 2,507 | $2K | |
| 96136 | <1% | 26 | $2K | |
| 88342 | <1% | 571 | $2K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 13 | $2K |
| 86762 | <1% | 805 | $2K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 19 | $2K |
| 82746 | <1% | 1,297 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,754 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,364 | $2K |
| 83615 | <1% | 1,575 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 107 | $2K |
| 84100 | <1% | 4,024 | $2K | |
| 86787 | <1% | 702 | $1K | |
| 73080 | <1% | 879 | $1K | |
| 77080 | <1% | 25 | $1K | |
| 84550 | <1% | 2,015 | $1K | |
| 86140 | <1% | 3,749 | $1K | |
| 83880 | <1% | 10,545 | $1K | |
| 73590 | <1% | 1,363 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,642 | $1K |
| 90688 | <1% | 70 | $1K | |
| 93880 | <1% | 27 | $1K | |
| 82570 | <1% | 2,486 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 834 | $1K |
| 82565 | <1% | 2,039 | $1K | |
| 70498 | <1% | 266 | $1K | |
| 82043 | <1% | 2,683 | $1K | |
| 81003 | <1% | 17,294 | $1K | |
| 72146 | <1% | 14 | $1K | |
| 83970 | <1% | 230 | $996.39 | |
| 95800 | <1% | 12 | $980.18 | |
| 81001 | <1% | 18,421 | $977.53 | |
| 90656 | <1% | 48 | $952.59 | |
| 86803 | <1% | 584 | $900.98 | |
| 29505 | <1% | 13 | $900.23 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,966 | $898.57 |
| 73700 | <1% | 30 | $888.77 | |
| 86901 | <1% | 5,451 | $831.19 | |
| 71101 | <1% | 294 | $826.57 | |
| 85652 | <1% | 3,442 | $787.44 | |
| 82075 | <1% | 2,644 | $774.97 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 26 | $773.44 |
| 86038 | <1% | 688 | $723.49 | |
| 80076 | <1% | 2,855 | $713.22 | |
| 77280 | <1% | 15 | $671.36 | |
| 97014 | <1% | 92 | $667.38 | |
| 83690 | <1% | 17,625 | $662.71 | |
| 82330 | <1% | 1,489 | $647.28 | |
| 72070 | <1% | 84 | $632.73 | |
| 88304 | <1% | 1,065 | $585.70 | |
| 88307 | <1% | 594 | $546.93 | |
| 84520 | <1% | 1,100 | $543.71 | |
| 84484 | <1% | 20,671 | $495.37 | |
| 84460 | <1% | 1,652 | $487.33 | |
| 84450 | <1% | 1,617 | $472.84 | |
| 80051 | <1% | 709 | $471.48 | |
| 84481 | <1% | 336 | $470.20 | |
| 87205 | <1% | 1,497 | $465.13 | |
| 80055 | <1% | 29 | $451.12 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 250 | $360.20 |
| 73200 | <1% | 12 | $359.03 | |
| 87147 | <1% | 492 | $355.35 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 26 | $312.08 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 3,121 | $311.68 |
| 85379 | <1% | 2,991 | $308.25 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 19 | $290.66 |
| 73090 | <1% | 820 | $283.93 | |
| 73620 | <1% | 115 | $279.40 | |
| 82150 | <1% | 2,638 | $265.07 | |
| 88341 | <1% | 103 | $257.30 | |
| 82950 | <1% | 256 | $233.80 | |
| 97035 | <1% | 42 | $221.22 | |
| 82140 | <1% | 629 | $201.26 | |
| 87040 | <1% | 3,185 | $198.77 | |
| 82550 | <1% | 872 | $197.22 | |
| 82247 | <1% | 252 | $184.51 | |
| 82248 | <1% | 254 | $179.32 | |
| 82077 | <1% | 3,595 | $173.06 | |
| 74022 | <1% | 734 | $172.90 | |
| 86431 | <1% | 390 | $170.77 | |
| 83655 | <1% | 120 | $169.14 | |
| 82803 | <1% | 700 | $167.05 | |
| 83605 | <1% | 7,499 | $163.69 | |
| 83721 | <1% | 183 | $147.99 | |
| 84153 | <1% | 73 | $130.60 | |
| 73560 | <1% | 29 | $128.28 | |
| 93017 | <1% | 44 | $127.92 | |
| 99152 | <1% | 2,353 | $125.85 | |
| 76870 | <1% | 67 | $122.14 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 250 | $116.46 |
| 72040 | <1% | 29 | $94.86 | |
| 73552 | <1% | 235 | $94.72 | |
| 12001 | <1% | 689 | $94.00 | |
| 81015 | <1% | 1,986 | $80.62 | |
| 80047 | <1% | 7,151 | $79.85 | |
| 84436 | <1% | 154 | $79.74 | |
| 87808 | <1% | 58 | $76.97 | |
| 85014 | <1% | 7,421 | $76.64 | |
| 73060 | <1% | 307 | $75.19 | |
| 80164 | <1% | 86 | $66.72 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,735 | $65.79 |
| 84156 | <1% | 172 | $59.71 | |
| 86696 | <1% | 38 | $56.53 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 50 | $54.15 |
| 84403 | <1% | 60 | $52.30 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,739 | $51.57 |
| 86695 | <1% | 38 | $50.97 | |
| 87449 | <1% | 2,221 | $50.91 | |
| 83516 | <1% | 42 | $49.39 | |
| 82378 | <1% | 12 | $49.10 | |
| 85018 | <1% | 874 | $47.54 | |
| 94760 | <1% | 12 | $46.95 | |
| 86376 | <1% | 44 | $46.45 | |
| 86800 | <1% | 16 | $46.24 | |
| 80069 | <1% | 24 | $43.82 | |
| 82784 | <1% | 54 | $42.27 | |
| 87634 | <1% | 113 | $39.54 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,731 | $37.68 |
| 90715 | <1% | 2,868 | $37.56 | |
| 90662 | <1% | 21 | $27.58 | |
| 84132 | <1% | 465 | $27.34 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 126 | $24.84 |
| 80143 | <1% | 126 | $23.37 | |
| 86706 | <1% | 27 | $19.96 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 872 | $19.88 |
| 87210 | <1% | 1,095 | $19.40 | |
| 82105 | <1% | 13 | $18.90 | |
| 82375 | <1% | 457 | $18.80 | |
| 87075 | <1% | 168 | $18.08 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,599 | $16.52 |
| 82948 | <1% | 619 | $15.67 | |
| 85046 | <1% | 51 | $15.40 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,610 | $15.38 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,061 | $14.34 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,120 | $13.11 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 18 | $11.94 |
| 80179 | <1% | 83 | $11.09 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 824 | $11.04 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 191 | $10.83 |
| 84075 | <1% | 31 | $10.49 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 465 | $7.89 |
| 82310 | <1% | 12 | $7.56 | |
| 84155 | <1% | 15 | $7.43 | |
| 86308 | <1% | 183 | $5.81 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,172 | $5.08 |
| 85347 | <1% | 29 | $4.78 | |
| 84630 | <1% | 12 | $3.77 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,810 | $3.77 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,710 | $3.28 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 27,276 | $2.69 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,444 | $1.77 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 711 | $1.28 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,702 | $1.16 |
| J2704 | Injection, propofol, 10 mg | <1% | 16,414 | $0.76 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,837 | $0.22 |
| A9270 | Non-covered item or service | <1% | 47,180 | $0.15 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,017 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 170 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 2,249 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 1,336 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 1,737 | $0.00 |
| 82010 | 0% | 589 | $0.00 | |
| 29125 | 0% | 176 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 339 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 149 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 291 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 179 | $0.00 |
| 76999 | 0% | 130 | $0.00 | |
| 84145 | 0% | 67 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 630 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 305 | $0.00 |
| 90461 | 0% | 283 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 732 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 563 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 724 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 420 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 510 | $0.00 |
| 88741 | 0% | 428 | $0.00 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 101 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 373 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
| 82652 | 0% | 13 | $0.00 | |
| 88302 | 0% | 14 | $0.00 | |
| 73140 | 0% | 13 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 31 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 12 | $0.00 |
| 99499 | 0% | 45 | $0.00 | |
| 88112 | 0% | 12 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 193 | $0.00 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 29 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 178 | $0.00 |
| 64999 | 0% | 41 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 14 | $0.00 |
| 76376 | 0% | 24 | $0.00 | |
| 77387 | 0% | 156 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 290 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 526 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 447 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 5,862 | $0.00 |
| 96376 | 0% | 5,932 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 474 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 1,528 | $0.00 |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 0% | 472 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 6,896 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 2,149 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 576 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 1,241 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 3,704 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 3,238 | $0.00 |
| 12002 | 0% | 132 | $0.00 | |
| C1769 | Guide wire | 0% | 2,689 | $0.00 |
| 74021 | 0% | 126 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 129 | $0.00 |
| 97010 | 0% | 2,222 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 415 | $0.00 |
| 85651 | 0% | 13 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 584 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 702 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 791 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 61 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 36 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 40 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 13 | $0.00 |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | 0% | 53 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 46 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 54 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 48 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 55 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 53 | $0.00 |
| 82553 | 0% | 41 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 12 | $0.00 |
| A9150 | Non-prescription drugs | 0% | 38 | $0.00 |
| 96368 | 0% | 15 | $0.00 | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 14 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 15 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 15 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 28 | $0.00 |
| 73600 | 0% | 16 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 15 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 14 | $0.00 |
| 72170 | 0% | 14 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 12 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 16 | $0.00 |
| 64415 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKORTE, FRED (VICE PRESIDENT/CFO)
| Provider | Location | Paid |
|---|---|---|
| Mclaren Lapeer Region | Lapeer, MI | $16.98M |
| Mclaren Flint | Flint, MI | $7.35M |
| Mclaren Lapeer Region | Lapeer, MI | $2.23M |
| Mclaren Flint | Flint, MI | $472K |
| Mclaren Flint | Flint, MI | $308K |
| Mclaren Flint | Flint, MI | $218K |
| Mclaren Flint | Flint, MI | $181K |
| Mclaren Flint | Flint, MI | $77K |
| Mclaren Flint | Flint, MI | $38K |
| Mclaren Lapeer Region | Lapeer, MI | $18K |
| Mclaren Lapeer Region | Lapeer, MI | $14K |
| Mclaren Lapeer Region | Lapeer, MI | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.